Back

Coated Bacterial Vaccine Platform Overcomes Weak Antigen Immunogenicity: A Functional Approach to GnRH-Based Immunocastration

Harguindeguy, I.; Assandri, M.; Daza Millone, A.; Cavalitto, S.; Serradell, M.; Ortiz, G.

2026-04-22 immunology
10.64898/2026.04.20.719670 bioRxiv
Show abstract

Immunocastration, a non surgical strategy based on active immunization against gonadotropin-releasing hormone (GnRH), effectively suppresses steroidogenesis and spermatogenesis. However, peptide vaccines targeting poorly immunogenic antigens such as GnRH often fail to elicit robust adaptive immune responses, requiring adjuvants or carrier proteins. Previously, we introduced Coated Bacterial Vaccines (CBVs), a platform that uses chemically inactivated Gram-positive bacteria to display recombinant antigens fused to the SlpA carboxy terminal domain (dSLPA) on their surface. This system leverages natural pathogen associated molecular patterns (PAMPs) to enhance immunogenicity without additional adjuvants. In this work, we extended the application of the CBVs platform to enhance the immune response against a poorly immunogenic GnRH-based peptide vaccine. GnRH-CBVs were formulated using inactivated Bacillus subtilis var. natto coated with a recombinant GnRH tandem repeat dSLPA fusion protein and administered to male BALB/c mice. A chitosan-adjuvanted GnRH dSLPA formulation served as a positive control. GnRH-CBVs induced a strong Th2-biased humoral response, characterized by predominant IgG1 levels comparable to those achieved with chitosan. The resulting antibodies effectively neutralized endogenous GnRH, reducing steroidogenesis and spermatogenesis and inducing marked testicular histological alterations. These findings support CBVs as a promising strategy to enhance peptide vaccine immunogenicity for veterinary immunocastration.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Vaccine
189 papers in training set
Top 0.2%
14.7%
2
Frontiers in Immunology
586 papers in training set
Top 0.8%
8.4%
3
Vaccines
196 papers in training set
Top 0.2%
8.4%
4
Scientific Reports
3102 papers in training set
Top 18%
6.4%
5
npj Vaccines
62 papers in training set
Top 0.1%
6.3%
6
Frontiers in Bioengineering and Biotechnology
88 papers in training set
Top 0.2%
6.3%
50% of probability mass above
7
Journal of Controlled Release
39 papers in training set
Top 0.3%
3.6%
8
PLOS ONE
4510 papers in training set
Top 39%
3.6%
9
Human Vaccines & Immunotherapeutics
25 papers in training set
Top 0.2%
3.6%
10
ACS Synthetic Biology
256 papers in training set
Top 1%
2.6%
11
Advanced Functional Materials
41 papers in training set
Top 1%
1.7%
12
Biomaterials
78 papers in training set
Top 0.7%
1.3%
13
Journal of Biomedical Materials Research Part A
18 papers in training set
Top 0.3%
1.2%
14
Advanced Science
249 papers in training set
Top 14%
1.2%
15
ACS Nano
99 papers in training set
Top 3%
0.9%
16
Vaccine: X
19 papers in training set
Top 0.3%
0.9%
17
Cell Reports Medicine
140 papers in training set
Top 6%
0.9%
18
Nature Communications
4913 papers in training set
Top 60%
0.9%
19
Cellular & Molecular Immunology
14 papers in training set
Top 2%
0.8%
20
Molecular Therapy
71 papers in training set
Top 3%
0.8%
21
Frontiers in Microbiology
375 papers in training set
Top 8%
0.8%
22
Frontiers in Plant Science
240 papers in training set
Top 5%
0.8%
23
Bioengineering & Translational Medicine
21 papers in training set
Top 0.9%
0.7%
24
Cell Discovery
54 papers in training set
Top 5%
0.7%
25
European Journal of Immunology
57 papers in training set
Top 0.6%
0.7%
26
mBio
750 papers in training set
Top 12%
0.7%
27
iScience
1063 papers in training set
Top 35%
0.7%
28
Antibody Therapeutics
16 papers in training set
Top 0.6%
0.6%
29
BMC Medicine
163 papers in training set
Top 8%
0.6%
30
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.4%
0.6%